|
|
|
| Efficacy of Shensong Yangxin Capsule on Ventricular Arrhythmia and its Effects on Serum β1-AAB Level |
| ZHANG Jing, LI Jun, TANG Sanhua |
| Liuzhou Liutie Central Hospital, Guangxi Liuzhou 545007, China |
|
|
|
|
Abstract Objective: To study the efficacy of Shensong Yangxin capsule on ventricular arrhythmia (VA) and its effects on serum anti-β1-adrenoceptor autoantibody (β1-AAB) level. Methods: 146 patients with VA in our hospital from January 2017 to December 2018 were selected and divided into two groups according to the random number table method, with 73 cases in each group. The two groups were treated with amiodarone, and observation group was additionally given Shensong Yangxin capsule on this basis, and they were treated for 2 months. The clinical efficacy, and electrocardiograph (ECG) indicators, serum β1-AAB, T lymphocyte subsets and occurrence of adverse reactions after treatment were compared between the two groups. Results: The effective rates of treatment were 94.52% and 83.56% in observation group and control group(P<0.05). After treatment, there were no significant changes in PR interval and QT interval between the two groups (P>0.05), and the QTcd, β1-AAB, CD4+ and CD4+/CD8+ in the two groups were significantly decreased (P<0.05) while the CD8+ was significantly increased in the two groups (P<0.05), and the change of PR interval before and after treatment in observation group was smaller than that in control group, and the changes of QT interval, QTcd, β1-AAB, CD4+ and CD4+/CD8+ before and after treatment were greater than those in control group (P<0.05). The incidence rates of adverse reactions in the two groups were 13.70% and 9.59% respectively (P>0.05). Conclusion: Shensong Yangxin capsule combined with amiodarone can shorten the cardioversion time and reduce the QTcd value, and it is also beneficial to reduce the level of serum β1-AAB and improve the distribution of T lymphocyte subsets, thus improving the treatment effects.
|
|
|
|
|
|
[1] 曹克将,陈明龙,江洪,等.室性心律失常中国专家共识[J].中国心脏起搏与心电生理杂志,2016,20(4):279~326.
[2] Tang PT,Shenasa M,Boyle NG.Ventricular arrhythmias and sudden cardiac death[J].Card Electrophysiol Clin,2017,9(4):693~708.
[3] Barman M.Proarrhythmic effects of antiarrhythmic drugs:case study of flecainide induced ventricular arrhythmias during treatment of atrial fibrillation[J].Atr Fibrillation,2015,8(4):1091~1094.
[4] 王会洪,黄鹤,任贻强.参松养心胶囊联合低剂量胺碘酮治疗室性心律失常的疗效分析[J].中国药房,2017,28(21):2926~2929.
[5] Hunt SA.ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Update the 2001 Guidelin[J].Am Coll Cardiol,2005,46(6):e1~e82.
[6] Priori SG,Blomstromlundqvist C,Mazzanti A,et al.2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the european[J].Rev Esp Cardiol(Engl Ed),2016,69(2):176~176.
[7] 张雨晴,刘旭东,何庆勇.运用经方治疗心律失常经验[J].世界中西医结合杂志,2017,12(3):322~325.
[8] 郭道群.参松养心胶囊对心律失常患者的双向调节作用[J].山西医药杂志,2017,46(07):832~833.
[9] 柳瑞.参松养心胶囊治疗心律失常65例疗效分析[J].中西医结合心脑血管病杂志,2016,14(21):2577~2580.
[10] Zhao Y,Gao F,Zhang Y,et al.Shensong Yangxin capsules prevent ischemic arrhythmias by prolonging action potentials and alleviating Ca2+overload[J].Mol Med Rep,2016,13(6):5185~5192. |
|
|
|
2019, Vol. 25 
